E-viri
Recenzirano
-
Weiss, Aaron R.; Dry, Sarah; Maygar, Clara; Cutler, Anya; Lary, Christine W.; Khoo, Carmen; Fergione, Jillian E.; Hounchell, Melanie M.; Glick, Kathleen; Browning, Meghen; Choo, Sun Ha; Hawkins, Douglas S.; Lagmay, Joanne; Manalang, Michelle; Skapek, Stephen X.; Weigel, Brenda; Verwys, Stephanie; Federman, Noah
Pediatric blood & cancer, September 2023, Letnik: 70, Številka: 9Journal Article
Deregulation of the mTOR pathway may play an important role in tumor biology when the APC/β‐catenin pathway is disrupted in desmoid‐type fibromatosis (DT). A pilot study was conducted to determine whether sirolimus can block the mTOR pathway (primary aim) as well as determine whether it can safely be given in the preoperative setting, decrease tumor size/recurrence, and decrease tumor‐associated pain in children and young adults (secondary aims) with DT. Nine subjects ages 5–28 years were enrolled from 2014 to 2017 across four centers. Sirolimus was feasible and was associated with a nonstatistically significant decrease in pS706K activation.
